カジノゲーム：バカラ（Baccarat） - MillionRaise

MENU Company Company Back Company Message from Top Management Our Founding Spirit Brand Statement Our Story Our History of Value Creation Vision and Strategy Framework Group Vision Long-Term Management Strategy Management Policy Medium-Term Management Plan Corporate Information and Business Sites Business Overview Introduction of Executives Corporate Governance Group Companies Procurement Policy Corporate Policy over Internal Control Integrated Report Products and Technology Products Back Products Search by Application Mobility Architectural Materials Infrastructure / General Industry Electronics Semiconductors Energy Daily commodities, Food industry Life Science Search by Business Category Architectural Glass Automotive Display Electronic Materials Essential Chemicals Performance Chemicals Life Science Ceramics New Business Search by Name Search by Keyword Technology and Innovation back Technology and Innovation A Message from the Chief Technology Officer Technology Development Strategy Intellectual Property Strategy R&D Structure Core Technologies Technology Highlights Mobility Electronics Life Science AGC Yokohama Technical Center AGC OPEN SQUARE “AO” Overview Facility Guide Access Collaboration Research Collaboration System R&D Library Measures to Prevent Misconduct in Research and Properly Manage Public Research Funds Sustainability Sustainability Back Sustainability Protecting the Global Environment and Utilizing Resources Supporting the Evolution of Cities and Mobility Realizing Longevity Society Where People Can Live in Good Health Creating a Healthy and Secure Society through Connections Generating New Value from Fair and Safe Workplaces Message from the President and CEO The AGC Group’s Sustainability Management Sustainability Promotion System Download Report Site Reports External Evaluations GRI Standards Index Sustainability-related policies, criteria, and guidelines AGC Group Code of Conduct/Compliance Help Lines Investors Investors Back Investors Management Information To Our Shareholders Vision and Strategy Framework Business Risks Disclosure Policy Financial Highlights IR News IR Library Company Overview Presentations of Financial Results Presentations of Business Briefings Financial Results Financial Review AGC Review (Newsletter for Shareholders) ESG Information Sustainability Corporate Governance Integrated Report Stock and Bond Information Stock Information Corporate Bond and Rating Information Dividend Information Analyst Coverage General Meeting of Shareholders Methods for Various Stock Procedures Electronic Public Notice Articles of Incorporation Stock Price Contact Us FAQ IR Email News Support Information IR Calendar Cautionary Statement IR Site Map Careers News Contact EN JP CN Search March 6, 2018Management Download PDF Print AGC Enhances Biopharmaceutical Production Capacity at AGC Biologics U.S. Berkeley Plant Installs New Bioreactor to Accelerate Scale-up Applications AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, has enhanced the production capacity of biopharmaceuticals at AGC Biologics (*1), AGC’s CDMO (*2) subsidiary. With this capital investment, its Berkeley Plant (California, USA) has doubled in capacity and starts full operation this March 2018. Berkeley Plant Mammalian Cell Bioreactor AGC Biologics is a CDMO with mammalian and microbial facilities, providing a range of high value-added services from process development, scale-up to commercial production. The Berkeley Plant specializes in projects from initial development to phase II (*3) biopharmaceutical production and contracted development, offering a broad range of services from cell bank (*4) production, storage, cell culture, and purification. With the newly installed single-use (*5) 2,000L mammalian cell bioreactor, the Berkeley Plant will be able to meet diverse customer requirements from initial development to Phase II production and rapidly respond to scale-up production requirements. In addition, this will enable AGC to provide clients with a smooth consistent interface, and high quality services backed by proven track records at all of the locations worldwide. Under its AGC plus management policy, the AGC Group has made a commitment to positioning its life-science business as one of its strategic initiatives. The AGC Group intends to continue making the necessary capital investment in its biopharmaceutical business, which is expected to exhibit significant growth in demand in the coming years. The AGC Group will continue to make a contribution to pharmaceutical companies, patients and society in general by maximizing synergies between each country and facility to enable a smooth and quick progression from development to commercial production. Notes *1 AGC has rebranded its Bioscience Business under the name AGC Biologics from January 2018. Accordingly, the legal entity name in the US operations, currently CMC Biologics, will be changed to AGC Biologics in 2018. *2 CDMO (Contract Development & Manufacturing Organization): A company that provides comprehensive services from development through manufacturing of biopharmaceuticals on a contract basis. *3 Phase II: Phase II clinical trials *4 Cell bank: Collection of cells of uniform composition *5 Single-use: Bioreactors that uses a disposable vessel. It reduces the need for cleaning and antimicrobial processes and minimizes the risk of contamination. REFERENCE ■AGC Group Bioscience Business Facilities Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations Division Contact: Yuki Kitano TEL: +81-3-3218-5603 E-mail: [email protected] Share News Index HomeNewsAGC Enhances Biopharmaceutical Production Capacity at AGC Biologics Check in AGC Site Map About Social Media Contact About This Site Privacy Policy ©AGC Inc.